[1] 董庆,崔健,辛衍忠,等.数字医学技术在非小细胞肺癌诊疗中的应用价值[J].中国数字医学,2013,8(7):87-89,92. [2] Petrovic M,Bukumiric Z,Zdravkovic V,et al.The prognostic significance of the circulating neuroendocrine markers chromogranin A,pro-gastrin-releasing peptide,and neuron-specific enolase in patients with small-cell lung cancer [J].Med Oncol,2014,31(2):823. [3] 徐俊,丁香彧,郭楠.小细胞肺癌患者血清胃泌素释放肽前体和神经元特异性烯醇化酶水平[J].中国老年学杂志,2015,35(05):1281-1282. [4] 钱希铭,王晓明,高亚英,等.小细胞肺癌患者化疗前后血清ProGRP、CEP350、NSE含量评估及其与疾病预后的关系[J].海南医学院学报,2016,22(16):1848-1850,1854. [5] Inomata M,Hayashi R,Yamamoto A,et al.Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib [J].Mol Clin Oncol,2015,3(4):802-806. [6] Huang Z,Xu D,Zhang F,et al.Pro-gastrin-releasing peptide and neuron-specific enolase:useful predictors of response to chemotherapy and survival in patients with small cell lung cancer [J].Clin Transl Oncol,2016,18(10):1019-1025. [7] 徐俊,丁香彧,郭楠.小细胞肺癌患者血清胃泌素释放肽前体和神经元特异性烯醇化酶水平[J].中国老年学杂志,2015,35(05):1281-1282. [8] Hirose T,Okuda K,Yamaoka T,et al.Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer [J].Lung Cancer,2011,71(2):224-228. [9] 张淑艳,胡晓芳.NSE和ProGRP联合检测在小细胞肺癌中的应用价值[J].中国热带医学,2015,15(4):466-468,476.
2018, Vol. 35 
